14 Melanoma Marches down, 7 to go!
19 March 2018
The weather varied, with high temps in Canberra, Bunbury, Manly and Newcastle, while Adelaide and Bunbury bore the brunt of wind and some rain. Needless to say, all six Marches were overwhelming successes.
Bendigo, with a population of less than 100,000 people, has raised a whopping $16,000 for Melanoma Institute Australia. This is incredible and the feedback has been amazing, with the committee working tirelessly to put on what was a great event.
It was a beautiful morning in Newcastle, there was a breeze and it was very scenic down near Nobby’s beach. While emotions ran high, the sense of community was undeniable, with everyone supporting one another and all Marching for the same cause. With over 300 people attending the March, Newcastle has broken the $30,000 fundraising tally mark, which is a huge achievement.
Manly had a change of location and added an additional challenge. Participants tackled stand-up-paddle boarding on a 3km loop, while the majority Marched collectively, following the Fairlight walking path. With nearly 500 people registering at Manly, the event was a huge success.
Canberra reached big numbers with over 300 participants attending the March this year. Our country’s capital always produces a great atmosphere for Marchers to show support to those who have been affected by melanoma.
Bunbury, a small town in Western Australia held Melanoma March, and, for the first time ever included a 10km optional running track. In partnership with melanomaWA, Melanoma March Bunbury contributed to raising life-saved funds for melanoma research. Thank you to the committee and to melanomaWA for their continued support.
Thank you to all participants, committee members, supporters and to all. Melanoma March is a time to remember, honour and support those who have had or have melanoma. But there is still work to be done. We still have 7 Marches in various states to go, so let’s not lose momentum. It is time to end melanoma.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.